FOCUS on Drug Approvals. On December 17th the FDA granted regular approval to PARP inhibitor drug Rubraca (Rucaparib, pharmaand GmbH), for treatment of adults with a […]

The FDA has approved the use of olaparib (Focus Cat.# 10-2154) as adjuvant treatment for patients with BRCA-mutated HER-2 negative high-risk early breast cancer that were […]